A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy

Trial Profile

A Randomised, Double-blind, Active-controlled Study to Evaluate the Impact of Stepwise Withdrawal of Inhaled Corticosteroid Treatment in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) on Optimized Bronchodilator Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol (Primary) ; Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Acronyms WISDOM
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 18 May 2016 Results (post hoc analysis, n = 262) assessing lung-function profile before and after the first moderate to severe exacerbation presented at the 112th International Conference of the American Thoracic Society.
    • 18 May 2016 Results of a post hoc subgroup analysis (n=2296) presented at the 112th International Conference of the American Thoracic Society
    • 08 Apr 2016 Results of a post-hoc analysis published in a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top